TGFB1 and osteoporosis: Clinical translation, however, requires challenges to be overcome, including achieving bone-specific targeting of TGF-β inhibitors (e.g., via bisphosphonate conjugation) and defining safe regimens for short-term blockade versus chronic management of osteoporosis.